drugset / Trial / NCT01321164

Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis

NCT01321164

Phase 3 Completed 30 enrolled Medical University of Vienna
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objective of the study is to evaluate the additional effect of a narrow band Type B Ultraviolet (UVB) therapy on the treatment of severe plaque psoriasis with fumaric acid esters (FAE) in comparison to FAE monotherapy. The secondary objectives are to evaluate the effect of an additional narrow band UVB therapy on the cumulative FAE dose required to reach Psoriasis Area and Severity Index (PASI) 75 in comparison to FAE monotherapy and to evaluate whether a leukopenia and lymphopenia frequently occurring during the FAE treatment is a positive predictive factor for the treatment response.

Timeline

Start
2011-04
Primary completion
2013-12
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fumaric acid Small molecule Oral

Indications